British National Formulary (BNF) 73
Joint Formulary Committee
73 (March 2017)
Published jointly by BMJ Publishing Group Ltd and Royal Pharmaceutical Society
NICE has accredited the editorial process used by the British National Formulary to produce its resources.*
New content updates in the BNF 73 include:
- Updated guidance for conditions including anal fissure, coeliac disease, dementia, exocrine pancreatic insufficiency, food allergy, multiple sclerosis and short bowel syndrome. New prescribing guidance for biological and biosimilar medicines.
- New drug monographs alirocumab, blinatumomab, brivaracetam, ceftobiprole, clevidipine, elvitegravir, isavuconazole, nivolumab and panobinostat.
- New safety information about fire risk with paraffin-based skin emollients on dressings and clothing and advice on minimising the risk of infections when being treated with idelalisib.
- Updated guidance on starting routine for oral progestogen-only contraceptives and the use of sodium glucose co-transporter 2 inhibitors as monotherapy for treating type 2 diabetes.
Improvements in the new edition:
Since the launch of the new format BNF we have actively sought your comments and feedback, and as a result have made the following improvements to this edition:
- Important safety information is displayed prominently within the monograph
- Class monographs (e.g. ACE inhibitors) are easy to navigate to from the individual monographs.
The BNF evaluates clinical evidence from diverse sources with information validated by a network of clinical experts and published under the authority of a Joint Formulary Committee.
RPS members qualify for a 50% discount on your initial copy of the BNF and BNFC - enter your membership number at the checkout.
*The accreditation is valid until 13 September 2021 and applies to resources produced using the accredited process. More information on NICE accreditation can be viewed at www.nice.org.uk/accreditation.
- ISSN 0260-535X
- ISBN 978 0 85711 276 7
- Published Mar 2017
210 x 148mm (1536pp)